To ensure the highest quality of scholarship and clinical utility, the Journal for Translational Respiratory Immunology (JTRI) mandates that all submissions adhere to the following unique author guidelines. These requirements are specifically designed to bridge the gap between basic immunological bench science and clinical respiratory practice.

The "Translational Impact" Statement

Every submission must include a Translational Impact Statement (150 words maximum) as the final paragraph of the Introduction. This section must explicitly address:

• The Clinical Gap: What is the unmet medical need in respiratory immunology?

• The Bridge: How does this specific study move a discovery from the laboratory (or computational model) toward a clinical application?

• Future Utility: What is the potential diagnostic or therapeutic implication for patient care?

Mandatory Data Transparency

JTRI requires authors to provide a Data and Material Availability Statement at the end of the manuscript.

• Open Data: Authors are strongly encouraged to deposit raw data (e.g., flow cytometry files, transcriptomic data, imaging datasets) in a public repository (e.g., GEO, Zenodo, Dryad).

• Reproducibility: If proprietary software or specialized laboratory protocols are used, sufficient technical documentation must be provided to allow for independent replication.

Specific Reporting Guidelines

To ensure rigorous reporting, authors must follow the relevant EQUATOR Network guidelines. Manuscripts not accompanied by the appropriate completed checklist may be returned without review:

• Clinical Trials: CONSORT guidelines.

• Systematic Reviews/Meta-analyses: PRISMA guidelines.

• Observational Studies: STROBE guidelines.

• Pre-clinical Animal Models: ARRIVE guidelines.

Ethical & AI Disclosure

• Authorship Integrity: JTRI strictly enforces ICMJE authorship standards. The "Author Contribution" section must detail the specific role of each author (e.g., "designed the research," "conducted flow cytometry," "performed statistical analysis," "provided clinical samples").

• Generative AI Policy: Authors using AI-assisted tools to draft text, summarize data, or edit for language must disclose this in the "Acknowledgments" section. AI cannot be listed as an author, and authors remain fully responsible for the accuracy of all generated content.

• Ethics Statement: Manuscripts involving human subjects must clearly state that the protocol was approved by an Institutional Review Board (IRB) and that informed consent was obtained.

Visual Abstract Requirement

To enhance the reach of translational research, authors are required to submit a Visual Abstract (a single graphic summary).

• This should be a high-quality, professional image (JPEG or TIFF, 300 DPI) that illustrates the study's central mechanism and clinical conclusion.

• The goal is to communicate the core "translational leap" of your research at a single glance.

Manuscript Structure

All submissions should be organized as follows:

1. Title Page: Title, author affiliations, ORCID IDs, and a clearly designated Corresponding Author with email address.

2. Abstract: Structured (Background, Methods, Results, Clinical Significance).

3. Introduction: Ending with the "Translational Impact" statement.

4. Materials & Methods: Must include detailed clinical cohort characteristics.

5. Results: Clearly separated from Discussion.

6. Discussion: Must address the limitations and potential clinical application.

7. Conclusion: Summary of findings.

8. References: Must be formatted in Vancouver style.

​​